Need to check their alerts and concerns on increasing resistance. Whether they agree with you, I can't speak for them.
From the CDC website:
Due to concerns about emerging gonococcal resistance to cephalosporins, CDC no longer recommends oral cephalosporins for treatment of gonococcal infections.
Resistance to azithromycin, an antibiotic used to treat gonorrhea, is emerging, according to CDC findings published today in the Morbidity and Mortality Weekly Report.
CDC currently recommends a combination gonorrhea treatment with two antibiotics – an oral dose of azithromycin and single shot of ceftriaxone. Findings released today from CDC’s surveillance system for monitoring the threat of antibiotic-resistant gonorrhea show that the percentage of gonorrhea isolates with decreased susceptibility to azithromycin, an indicator of emerging resistance, increased more than 400 percent between 2013 and 2014 (from 0.6 percent to 2.5 percent of gonorrhea isolates). This is a distressing sign that the future of current treatment options may be in jeopardy and underscores the importance of the federal government’s Combating Antibiotic Resistant Bacteria (CARB) Action Plan.
“The confluence of emerging drug resistance and very limited alternative options for treatment creates a perfect storm for future gonorrhea treatment failure in the U.S.,” said Jonathan Mermin, M.D., director of the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and Tuberculosis Prevention. “History shows us that bacteria will find a way to outlast the antibiotics we’re using to treat it. We are running just one step ahead in order to preserve the remaining treatment option for as long as possible.”
There were recent alerts issued which I won't go into here.
The safety profile for Brilacidin I would hope would be superior to Amoxicillin. More restrictions coming for the drugs you mentioned, let alone the alarming resistance for each of them.
Its a possibility until its not a possibility. Shorts are bailing now, a lot of buyers.
So are you saying the patent they have which covers the derivative structure, method and medical use is worthless? Wondering why the USPTO gave them that covered?
I agree they are all continuing to harp on P when it's not what the value proposition is here. Which is why we have a lot of shorts posting here driving away the focus to trivial BS. I think B-OM is the start of the lift in share price and a partnership. I think we have few nut cases posting here.
Rumored to the $130 to $150. What is odd if that is the fair value why would you sell, even if the BO doesn't happen? Then it could happen. So sell if you want, doesn't make much sense to me.
But he made a stellar hire, which matches what he has said in recent PRs he was going to do. You seem to be coming unhinged. Have you taken your med's lately?
The author wrote it and published it without apparent knowledge of CTIX's recent hire. Leo has stated he is building a management team that can move the drugs to commercialization.
Its Imagration yes but not for taking jobs, it's they are a total load on Britain, which is a an alien world for them. In other words they are nonfunctional, young adults creating crime, adults and elderly hitting the healthcare system hard, etc. The Brits would love them to work and be productive, it's not turning out that way. I travel to Britain 2 times a month on business, you don't have a clue what you are talking about. It's happening in the USA just like Britain and the rest.of EU.
BMRN would be a much better move than MDVN. SNY should really make the move and dump MDVN. IMHO.
It is only bogus if you don't know what your talking about. Then it is anything you can make up in your mind becomes true.
I read the report, CS mentioned BMRM is streamlining their development to focus on $500M plus drugs. This is most likely a good thing, BMRM's management knows what they are doing. Not sure what the out license agreement contains, but the Pompeii drug has promise based on results so far., just not a $500M + drug. They also modeled the take out price to as high as $139, depending on synergies SNY may gain from.
Instead of buying some of these biotech's on the cheap. Let's hunker down and man the fort. Great vision from GILD's management team.
You are posting frantically now, with meaningless posts. Starting a new trial is not cheerleading BiteMe.